Vitoc Vlad reported grant involving 800,000 derivative units of MAIA Biotechnology, Inc. at $0.00 for $0 on May 29, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Executive Officer
Chief Executive Officer
Filed Jun 1, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
800,000Stock Options
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
800,000Direct
Trade date
May 29, 2026Grant
Filed
Jun 1, 2026, 8:54 AM ET3-day reporting delay
Accession
0001878313-26-000053Code A · Transaction 388830
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MAIA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MAIA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago 0%1w ago −1.5%1d ago −0.8%
Returns since7d −2.3%30d +10%90d +2.3%180d1y

Footnotes in full

F1: The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.